| Click here to see a web copy of this news release | |
|
FOR IMMEDIATE RELEASE The Hallmarks of Major Chronic Diseases: A Unified Systems Biology ViewRichard Z. Cheng, M.D., Ph.D. AbstractOver the past decade, "hallmarks" frameworks have been used to distill the core mechanisms underlying aging and cancer. Similar hallmark-style mechanisms are now recognized across nearly all major chronic diseases, including diabetes, fatty liver disease, cardiovascular disease, neurodegeneration, autoimmune disorders, chronic kidney disease, psychiatric illness, and metabolic syndrome. Despite different clinical labels, these conditions converge on a common set of biological disruptions: mitochondrial dysfunction, metabolic dysregulation, oxidative stress, immune imbalance, hormonal disruption, microbiome disturbances, and impaired detoxification and repair. However, these hallmarks-while mechanistically accurate-do not identify the upstream causes that trigger them. Mechanisms describe what goes wrong inside cells, but not why. For example, the somatic mutation theory of cancer does not address what causes genomic instability, and mitochondrial dysfunction theories do not explain what initiates mitochondrial injury. Without identifying and correcting root causes, disease prevention or reversal is impossible. The Ten Root Drivers of Chronic Disease proposed in Integrative Orthomolecular Medicine (IOM)-environmental toxins, dietary and metabolic stressors, micronutrient deficiencies, chronic infections and immune dysregulation, hormonal imbalance, lifestyle factors, psychosocial stress, developmental and early-life programming, genetic/epigenetic susceptibility, and medical iatrogenesis -provide the causal foundation that the hallmark frameworks lack. These root drivers generate the hallmark mechanisms, and their differing combinations determine disease expression across tissues and organ systems. This unified systems-biology framework explains why diverse chronic diseases share similar mechanisms, and why restoring the cellular environment-through nutrient repletion, mitochondrial support, metabolic correction, detoxification, and immune balance-can improve or reverse multiple chronic conditions simultaneously. As argued below, these shared mechanisms arise from a finite set of upstream biological insults-the Ten Root Drivers of Chronic Disease. IntroductionThe "Hallmarks of Aging" [1, 2] and "Hallmarks of Cancer" [3, 4] frameworks are now firmly established in biomedical science. These models have helped organize complex fields around a core set of biological processes-genomic instability, mitochondrial dysfunction, disrupted proteostasis, chronic inflammation, metabolic rewiring, and more. However, the same mechanistic themes appear repeatedly across other chronic diseases, even though they are seldom presented as such in clinical medicine. Diabetes, fatty liver disease, cardiovascular disease, neurodegenerative conditions, autoimmune disorders, chronic kidney disease, depression, and autism-each has its own hallmark-style literature, yet the shared biological roots remain underappreciated. This review organizes these mechanisms side-by-side, demonstrating that chronic diseases represent divergent clinical endpoints of a convergent biological disturbance. Hallmarks of Major Chronic DiseasesBelow is a concise synthesis of the key hallmark mechanisms across major diseases, with representative citations. 1. Type 2 Diabetes & Metabolic SyndromeHallmarks [5-8]
2. Nonalcoholic Fatty Liver Disease (NAFLD) / NASHHallmarks [9-12]
3. Atherosclerosis / Coronary Artery DiseaseHallmarks [13-16]
4. Heart FailureHallmarks [17-20]
5. Alzheimer's Disease & NeurodegenerationHallmarks [21-24]
6. Parkinson's DiseaseHallmarks [25-27]
7. Autoimmune Diseases (RA, Hashimoto's, SLE, etc.)Hallmarks [28-31]
8. Chronic Kidney Disease (CKD)Hallmarks [32-35]
9. Depression & Mood DisordersHallmarks [36-39]
10. Autism Spectrum Disorder (ASD)Hallmarks [40-42]
11. ObesityHallmarks [43-46]
12. HypertensionHallmarks [47-50]
13. Cancer (Hallmarks of Cancer)
14. Aging (Hallmarks of Aging)Hallmarks [1, 2]
The Ten Root Drivers of Chronic Disease: The Upstream Causes Behind All Hallmark MechanismsWhile hallmark mechanisms explain how chronic diseases develop at the cellular level, they do not reveal why these mechanisms arise. Integrative Orthomolecular Medicine (IOM) identifies Ten Root Drivers of Chronic Disease-the true upstream biological insults that generate the hallmark mechanisms observed across all major chronic illnesses [52]. These root drivers are:
Different combinations and intensities of these ten drivers initiate the hallmark mechanisms-mitochondrial dysfunction, oxidative stress, metabolic dysregulation, immune imbalance, impaired detoxification, and others. Thus, chronic diseases are not fundamentally separate entities but diverse expressions of the same upstream biological disturbances acting on different tissues and organ systems. Cross-Disease Convergence: The Unifying PatternWhen the hallmark frameworks of major chronic diseases are compared side-by-side, they reveal a striking convergence at the mechanistic level. Despite different clinical diagnoses, these diseases consistently involve disruptions in the same fundamental cellular processes: Shared Mechanistic Axes
Critically, every one of these convergent mechanisms can be traced back to the same upstream origins: the Ten Root Drivers of Chronic Disease [52]. These root drivers initiate the mechanistic failures, and the specific combination and intensity of root drivers in an individual determine which mechanisms dominate-and thus which disease develops. This convergence explains why:
Implications for Integrative Orthomolecular Medicine (IOM)This unified systems biology perspective supports the IOM principle that: Chronic diseases are not many diseases, but different manifestations of the same underlying biological imbalances. Addressing these imbalances-nutrients, mitochondria, inflammation, toxins, hormones, metabolism, microbiome-often leads to improvement across multiple diagnoses simultaneously. This is why IOM frequently achieves outcomes unexplained by disease-specific medicine, such as:
ConclusionHallmark frameworks across chronic diseases reveal a profound truth: the biology of chronic illness is unified, not fragmented. Instead of treating diseases as isolated entities, a root-cause approach recognizes the true upstream drivers-environmental toxins, metabolic and dietary stressors, micronutrient deficiencies, chronic infections and immune dysregulation, hormonal imbalance, lifestyle and psychosocial stress, developmental programming, genetic/epigenetic susceptibility, and medical iatrogenesis-which initiate the hallmark mechanisms that ultimately produce chronic disease. When these root drivers are identified and corrected, the downstream mechanisms they disrupt-such as mitochondrial dysfunction, metabolic instability, oxidative stress, and impaired repair-can begin to normalize, allowing the body's intrinsic healing processes to re-emerge. This perspective forms the scientific foundation of Integrative Orthomolecular Medicine, offering a coherent, mechanistically grounded path toward genuine disease reversal and longevity. About the AuthorRichard Z. Cheng, M.D., Ph.D. - Editor-in-Chief, Orthomolecular Medicine News Service (orthomolecular.org) Dr. Cheng is a U.S.-based, NIH-trained, board-certified physician specializing in integrative cancer therapy, orthomolecular medicine, functional & anti-aging medicine. He maintains active practices in both the United States and China. A Hall of Fame inductee of the International Society for Orthomolecular Medicine and a Fellow of the American Academy of Anti-Aging & Regenerative Medicine (A4M), Dr. Cheng is widely recognized for his work on nutrition-based, root-cause reversal of chronic disease. He co-founded the China Low Carb Medicine Alliance and serves as an expert reviewer for the South Carolina Board of Medical Examiners. Dr. Cheng is the author of the forthcoming book 21st Century Medicine: Integrative Orthomolecular Medicine for Chronic Disease Reversal and Longevity, which outlines a unified framework combining functional medicine, metabolic therapy, and orthomolecular nutrition. He also offers online Integrative Orthomolecular Medicine consultation services. References:1. López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The Hallmarks of Aging. Cell 2013, 153, (6), 1194-1217. DOI: 10.1016/j.cell.2013.05.039 . 2. López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. Hallmarks of Aging: An Expanding Universe. Cell 2023, 186, (2), 243-278. DOI: 10.1016/j.cell.2022.11.001 . 3. Hanahan, D. Hallmarks of Cancer: New Dimensions. Cancer Discov 2022, 12, (1), 31-46. DOI: 10.1158/2159-8290.CD-21-1059 . 4. Hanahan, D.; Weinberg, R.A. The Hallmarks of Cancer. Cell 2000, 100, (1), 57-70. DOI: 10.1016/s0092-8674(00)81683-9 . 5. Fonseca, V.A. Defining and Characterizing the Progression of Type 2 Diabetes. Diabetes Care 2009, 32 Suppl 2, (Suppl 2), S151-156. DOI: 10.2337/dc09-S301 . 6. Vilas-Boas, E.A.; Almeida, D.C.; Roma, L.P.; Ortis, F.; Carpinelli, A.R. Lipotoxicity and β-Cell Failure in Type 2 Diabetes: Oxidative Stress Linked to NADPH Oxidase and ER Stress. Cells 2021, 10, (12), 3328. DOI: 10.3390/cells10123328 . 7. Kim, J.-A.; Wei, Y.; Sowers, J.R. Role of Mitochondrial Dysfunction in Insulin Resistance. Circ Res 2008, 102, (4), 401-414. DOI: 10.1161/CIRCRESAHA.107.165472 . 8. Datta, D.; Kundu, R.; Basu, R.; Chakrabarti, P. Pathophysiological Hallmarks in Type 2 Diabetes Heterogeneity (Review). Diabetol Int 2025, 16, (2), 201-222. DOI: 10.1007/s13340-024-00783-w . 9. Sharma, B.; John, S. Nonalcoholic Steatohepatitis (NASH). In StatPearlsStatPearls Publishing, Treasure Island (FL), 2025.; Available online: http://www.ncbi.nlm.nih.gov/books/NBK470243/. 10. Hughey, C.C.; Puchalska, P.; Crawford, P.A. Integrating the Contributions of Mitochondrial Oxidative Metabolism to Lipotoxicity and Inflammation in NAFLD Pathogenesis. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2022, 1867, (11), 159209. DOI: 10.1016/j.bbalip.2022.159209 ; Available online: https://www.sciencedirect.com/science/article/pii/S1388198122000993. 11. Durand, M.; Coué, M.; Croyal, M.; Moyon, T.; Tesse, A.; Atger, F.; Ouguerram, K.; Jacobi, D. Changes in Key Mitochondrial Lipids Accompany Mitochondrial Dysfunction and Oxidative Stress in NAFLD. Oxidative Medicine and Cellular Longevity 2021, 2021, (1), 9986299. DOI: 10.1155/2021/9986299 ; Available online: https://onlinelibrary.wiley.com/doi/abs/10.1155/2021/9986299. 12. Samy, A.M.; Kandeil, M.A.; Sabry, D.; Abdel-Ghany, A.A.; Mahmoud, M.O. From NAFLD to NASH: Understanding the Spectrum of Non-Alcoholic Liver Diseases and Their Consequences. Heliyon 2024, 10, (9), e30387. DOI: 10.1016/j.heliyon.2024.e30387; Available online: https://www.sciencedirect.com/science/article/pii/S2405844024064181. 13. Libby, P.; Buring, J.E.; Badimon, L.; Hansson, G.K.; Deanfield, J.; Bittencourt, M.S.; Tokgözoğlu, L.; Lewis, E.F. Atherosclerosis. Nat Rev Dis Primers 2019, 5, (1), 56. DOI: 10.1038/s41572-019-0106-z ; Available online: https://www.nature.com/articles/s41572-019-0106-z. 14. He, Z.; Luo, J.; Lv, M.; Li, Q.; Ke, W.; Niu, X.; Zhang, Z. Characteristics and Evaluation of Atherosclerotic Plaques: An Overview of State-of-the-Art Techniques. Front Neurol 2023, 14, 1159288. DOI: 10.3389/fneur.2023.1159288 . 15. Pahwa, R.; Jialal, I. Atherosclerosis. In StatPearlsStatPearls Publishing, Treasure Island (FL), 2025.; Available online: http://www.ncbi.nlm.nih.gov/books/NBK507799/. 16. Jebari-Benslaiman, S.; Galicia-García, U.; Larrea-Sebal, A.; Olaetxea, J.R.; Alloza, I.; Vandenbroeck, K.; Benito-Vicente, A.; Martín, C. Pathophysiology of Atherosclerosis. Int J Mol Sci 2022, 23, (6), 3346. DOI: 10.3390/ijms23063346 . 17. Narayan, S.I.; Terre, G.V.; Amin, R.; Shanghavi, K.V.; Chandrashekar, G.; Ghouse, F.; Ahmad, B.A.; S, G.N.; Satram, C.; Majid, H.A.; Bayoro, D.K. The Pathophysiology and New Advancements in the Pharmacologic and Exercise-Based Management of Heart Failure With Reduced Ejection Fraction: A Narrative Review. Cureus 2023, 15, (9), e45719. DOI: 10.7759/cureus.45719 . 18. Kumric, M.; Kurir, T.T.; Bozic, J.; Slujo, A.B.; Glavas, D.; Miric, D.; Lozo, M.; Zanchi, J.; Borovac, J.A. Pathophysiology of Congestion in Heart Failure: A Contemporary Review. 2024.; Available online: https://www.cfrjournal.com/articles/pathophysiology-congestion-heart-failure-contemporary-review?language_content_entity=en. 19. Budde, H.; Hassoun, R.; Mügge, A.; Kovács, Á.; Hamdani, N. Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction. Front Physiol 2022, 13, 928232. DOI: 10.3389/fphys.2022.928232 . 20. Heart Failure: Background, Etiology, Pathophysiology. 2025.; Available online: https://emedicine.medscape.com/article/163062-overview?&icd=login_success_email_match_fpf. 21. Sanabria-Castro, A.; Alvarado-Echeverría, I.; Monge-Bonilla, C. Molecular Pathogenesis of Alzheimer's Disease: An Update. Ann Neurosci 2017, 24, (1), 46-54. DOI: 10.1159/000464422 . 22. Abubakar, M.B.; Sanusi, K.O.; Ugusman, A.; Mohamed, W.; Kamal, H.; Ibrahim, N.H.; Khoo, C.S.; Kumar, J. Alzheimer's Disease: An Update and Insights Into Pathophysiology. Front. Aging Neurosci. 2022, 14. DOI: 10.3389/fnagi.2022.742408 ; Available online: https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2022.742408/full. 23. Zhang, J.; Zhang, Y.; Wang, J.; Xia, Y.; Zhang, J.; Chen, L. Recent Advances in Alzheimer's Disease: Mechanisms, Clinical Trials and New Drug Development Strategies. Sig Transduct Target Ther 2024, 9, (1), 211. DOI: 10.1038/s41392-024-01911-3 ; Available online: https://www.nature.com/articles/s41392-024-01911-3. 24. Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological Alterations in Alzheimer Disease. Cold Spring Harb Perspect Med 2011, 1, (1), a006189. DOI: 10.1101/cshperspect.a006189 . 25. Parkinson Disease: Background, Epidemiology, Anatomy. 2025.; Available online: https://emedicine.medscape.com/article/1831191-overview. 26. MacMahon Copas, A.N.; McComish, S.F.; Fletcher, J.M.; Caldwell, M.A. The Pathogenesis of Parkinson's Disease: A Complex Interplay Between Astrocytes, Microglia, and T Lymphocytes? Front. Neurol. 2021, 12. DOI: 10.3389/fneur.2021.666737 ; Available online: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.666737/full. 27. Wilson, D.M.; Cookson, M.R.; Van Den Bosch, L.; Zetterberg, H.; Holtzman, D.M.; Dewachter, I. Hallmarks of Neurodegenerative Diseases. Cell 2023, 186, (4), 693-714. DOI: 10.1016/j.cell.2022.12.032 ; Available online: https://www.sciencedirect.com/science/article/pii/S0092867422015756. 28. Xiang, Y.; Zhang, M.; Jiang, D.; Su, Q.; Shi, J. The Role of Inflammation in Autoimmune Disease: A Therapeutic Target. Front. Immunol. 2023, 14. DOI: 10.3389/fimmu.2023.1267091 ; Available online: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1267091/full. 29. Song, Y.; Li, J.; Wu, Y. Evolving Understanding of Autoimmune Mechanisms and New Therapeutic Strategies of Autoimmune Disorders. Sig Transduct Target Ther 2024, 9, (1), 263. DOI: 10.1038/s41392-024-01952-8 ; Available online: https://www.nature.com/articles/s41392-024-01952-8. 30. Pisetsky, D.S. Pathogenesis of Autoimmune Disease. Nat Rev Nephrol 2023, 19, (8), 509-524. DOI: 10.1038/s41581-023-00720-1 . 31. What Are Autoimmune Diseases? Available online: https://my.clevelandclinic.org/health/diseases/21624-autoimmune-diseases (accessed 30 November 2025). 32. Chronic Kidney Disease (CKD): Background, Etiology, Pathophysiology. 2025.; Available online: https://emedicine.medscape.com/article/238798-overview. 33. Altamura, S.; Pietropaoli, D.; Lombardi, F.; Del Pinto, R.; Ferri, C. An Overview of Chronic Kidney Disease Pathophysiology: The Impact of Gut Dysbiosis and Oral Disease. Biomedicines 2023, 11, (11), 3033. DOI: 10.3390/biomedicines11113033 . 34. Vaidya, S.R.; Aeddula, N.R. Chronic Kidney Disease. In StatPearlsStatPearls Publishing, Treasure Island (FL), 2025.; Available online: http://www.ncbi.nlm.nih.gov/books/NBK535404/. 35. Galvan, D.L.; Green, N.H.; Danesh, F.R. The Hallmarks of Mitochondrial Dysfunction in Chronic Kidney Disease. Kidney Int 2017, 92, (5), 1051-1057. DOI: 10.1016/j.kint.2017.05.034 . 36. Menezes Galvão, A.C. de; Almeida, R.N.; Sousa, G.M. de; Leocadio-Miguel, M.A.; Palhano-Fontes, F.; Araujo, D.B. de; Lobão-Soares, B.; Maia-de-Oliveira, J.P.; Nunes, E.A.; Hallak, J.E.C.; Schuch, F.B.; Sarris, J.; Galvão-Coelho, N.L. Pathophysiology of Major Depression by Clinical Stages. Front. Psychol. 2021, 12. DOI: 10.3389/fpsyg.2021.641779 ; Available online: https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2021.641779/full. 37. Socci, V.; Fagnani, L.; Barlattani, T.; Celenza, G.; Rossi, A.; Pacitti, F. Future Research Perspectives on Energy Metabolism and Mood Disorders: A Brief Narrative Review on Metabolic Status, Mitochondrial Hypothesis and Potential Biomarkers: Energy Metabolism and Mood Disorders. Italian Journal of Psychiatry 2025. DOI: 10.36180/2421-4469-2025-653 ; Available online: https://www.italianjournalofpsychiatry.it/article/view/653. 38. Chand, S.P.; Arif, H. Depression. In StatPearlsStatPearls Publishing, Treasure Island (FL), 2025.; Available online: http://www.ncbi.nlm.nih.gov/books/NBK430847/. 39. Cui, L.; Li, S.; Wang, S.; Wu, X.; Liu, Y.; Yu, W.; Wang, Y.; Tang, Y.; Xia, M.; Li, B. Major Depressive Disorder: Hypothesis, Mechanism, Prevention and Treatment. Sig Transduct Target Ther 2024, 9, (1), 30. DOI: 10.1038/s41392-024-01738-y ; Available online: https://www.nature.com/articles/s41392-024-01738-y. 40. Khaliulin, I.; Hamoudi, W.; Amal, H. The Multifaceted Role of Mitochondria in Autism Spectrum Disorder. Mol Psychiatry 2025, 30, (2), 629-650. DOI: 10.1038/s41380-024-02725-z . 41. Balachandar, V.; Rajagopalan, K.; Jayaramayya, K.; Jeevanandam, M.; Iyer, M. Mitochondrial Dysfunction: A Hidden Trigger of Autism? Genes Dis 2021, 8, (5), 629-639. DOI: 10.1016/j.gendis.2020.07.002 . 42. Rossignol, D.A.; Frye, R.E. Mitochondrial Dysfunction in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis. Mol Psychiatry 2012, 17, (3), 290-314. DOI: 10.1038/mp.2010.136 . 43. Kong, Y.; Yang, H.; Nie, R.; Zhang, X.; Zuo, F.; Zhang, H.; Nian, X. Obesity: Pathophysiology and Therapeutic Interventions. Mol Biomed 2025, 6, (1), 25. DOI: 10.1186/s43556-025-00264-9 . 44. Schwartz, M.W.; Seeley, R.J.; Zeltser, L.M.; Drewnowski, A.; Ravussin, E.; Redman, L.M.; Leibel, R.L. Obesity Pathogenesis: An Endocrine Society Scientific Statement. Endocr Rev 2017, 38, (4), 267-296. DOI: 10.1210/er.2017-00111 ; Available online: https://doi.org/10.1210/er.2017-00111. 45. Lin, X.; Li, H. Obesity: Epidemiology, Pathophysiology, and Therapeutics. Front. Endocrinol. 2021, 12. DOI: 10.3389/fendo.2021.706978 ; Available online: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.706978/full. 46. Busebee, B.; Ghusn, W.; Cifuentes, L.; Acosta, A. Obesity: A Review of Pathophysiology and Classification. Mayo Clin Proc 2023, 98, (12), 1842-1857. DOI: 10.1016/j.mayocp.2023.05.026 . 47. Martinez-Quinones, P.; McCarthy, C.G.; Watts, S.W.; Klee, N.S.; Komic, A.; Calmasini, F.B.; Priviero, F.; Warner, A.; Chenghao, Y.; Wenceslau, C.F. Hypertension Induced Morphological and Physiological Changes in Cells of the Arterial Wall. Am J Hypertens 2018, 31, (10), 1067-1078. DOI: 10.1093/ajh/hpy083 . 48. Nguyen, B.A.; Alexander, M.R.; Harrison, D.G. Immune Mechanisms in the Pathophysiology of Hypertension. Nat Rev Nephrol 2024, 20, (8), 530-540. DOI: 10.1038/s41581-024-00838-w . 49. Bousseau, S.; Fais, R.S.; Gu, S.; Frump, A.; Lahm, T. Pathophysiology and New Advances in Pulmonary Hypertension. bmjmed 2023, 2, (1). DOI: 10.1136/bmjmed-2022-000137 ; Available online: https://bmjmedicine.bmj.com/content/2/1/e000137. 50. Harrison, D.G.; Coffman, T.M.; Wilcox, C.S. Pathophysiology of Hypertension: The Mosaic Theory and Beyond. Circ Res 2021, 128, (7), 847-863. DOI: 10.1161/CIRCRESAHA.121.318082 . 51. Seyfried, T.N. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer; Wiley, 2012.; Available online: https://www.wiley.com/en-us/Cancer+as+a+Metabolic+Disease%3A+On+the+Origin%2C+Management%2C+and+Prevention+of+Cancer-p-9780470584927. 52. Cheng, R.Z. From Mutation to Metabolism: Root Cause Analysis of Cancer's Initiating Drivers. 2025. DOI: 10.20944/preprints202509.0903.v1 ; Available online: https://www.preprints.org/manuscript/202509.0903/v1. 53. Cheng, R.; Duan, L.; Levy, T. A Holistic Approach to ASCVD:Summary of a Novel Framework and Report of 10 Case Studies. Orthomolecular Medicine News Service 2024, 20, (20).; Available online: https://orthomolecular.org/resources/omns/v20n20.shtml. 54. Cheng, R.Z. Biden's Prostate Cancer and a 92-Year-Old Survivor: Rethinking Treatment through Metabolic Cancer Therapy. Orthomolecular Medicine News Service. 2025, 21, (33).; Available online: https://orthomolecular.org/resources/omns/v21n33.shtml. Orthomolecular MedicineOrthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information: http://www.orthomolecular.org Find a DoctorTo locate an orthomolecular physician near you: http://orthomolecular.org/resources/omns/v06n09.shtml The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource. Editorial Review Board:Jennifer L. Aliano, M.S., L.Ac., C.C.N. (USA) Comments and media contact: editor@orthomolecular.org OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication. Click here to see a web copy of this news release: http://orthomolecular.activehosted.com/p_v.php?c=514&m=429&s=bad97c655476f96a390a72c05a742011&d=0&v=2&l |
|
|
This news release was sent to _t.e.s.t_@example.com. If you no longer wish to receive news releases, please reply to this message with "Unsubscribe" in the subject line or simply click on the following link: unsubscribe . To update your profile settings click here . This article may be reprinted free of charge provided 1) that there is clear attribution to the Orthomolecular Medicine News Service, and 2) that both the OMNS free subscription link http://orthomolecular.org/subscribe.html and also the OMNS archive link http://orthomolecular.org/resources/omns/index.shtml are included.
|
|
